|
 The study showed that Lynparza was successful as a first-line
maintenance treatment for adults with a form of genetically-mutated
pancreatic cancer called germline BRCA -mutated metastatic
adenocarcinoma of the pancreas.
Lynparza, which is currently being used as a treatment for ovarian
and breast cancers, showed it was better at delaying the rare
pancreatic cancer from getting worse in patients when compared to a
placebo.
Maintenance therapy means prolonged use and likely higher sales for
AstraZeneca, whose new cancer drugs led by Tagrisso, Imfinzi and
Lynparza helped it turnaround its drug sales.
[to top of second column] |
Lynparza was abandoned at one time by AstraZeneca, but was revived
by Chief Executive Officer Pascal Soriot when he took over in 2012.
The drug became the first PARP drug to reach the market when it won
U.S. approval for ovarian cancer at the end of 2014.
PARP inhibitors work by blocking enzymes involved in repairing
damaged DNA of cancer cells, thereby helping to kill them.
AstraZeneca said it plans to discuss results of the study with
regulators across the world, but has not disclosed a specific time
frame.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak
Dasgupta, Bernard Orr)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
